Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Attenuating persistent sodium current–induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress
Uma Mahesh R. Avula, Haikel Dridi, Bi-xing Chen, Qi Yuan, Alexander N. Katchman, Steven R. Reiken, Amar D. Desai, Samantha Parsons, Haajra Baksh, Elaine Ma, Parmanand Dasrat, Ruiping Ji, Yejun Lin, Christine Sison, W. Jonathan Lederer, Humberto C. Joca, Christopher W. Ward, Maura Greiser, Andrew R. Marks, Steven O. Marx, Elaine Y. Wan
Uma Mahesh R. Avula, Haikel Dridi, Bi-xing Chen, Qi Yuan, Alexander N. Katchman, Steven R. Reiken, Amar D. Desai, Samantha Parsons, Haajra Baksh, Elaine Ma, Parmanand Dasrat, Ruiping Ji, Yejun Lin, Christine Sison, W. Jonathan Lederer, Humberto C. Joca, Christopher W. Ward, Maura Greiser, Andrew R. Marks, Steven O. Marx, Elaine Y. Wan
View: Text | PDF
Research Article Cardiology

Attenuating persistent sodium current–induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress

  • Text
  • PDF
Abstract

Mechanistically driven therapies for atrial fibrillation (AF), the most common cardiac arrhythmia, are urgently needed, the development of which requires improved understanding of the cellular signaling pathways that facilitate the structural and electrophysiological remodeling that occurs in the atria. Similar to humans, increased persistent Na+ current leads to the development of an atrial myopathy and spontaneous and long-lasting episodes of AF in mice. How increased persistent Na+ current causes both structural and electrophysiological remodeling in the atria is unknown. We crossbred mice expressing human F1759A-NaV1.5 channels with mice expressing human mitochondrial catalase (mCAT). Increased expression of mCAT attenuated mitochondrial and cellular reactive oxygen species (ROS) and the structural remodeling that was induced by persistent F1759A-Na+ current. Despite the heterogeneously prolonged atrial action potential, which was unaffected by the reduction in ROS, the incidences of spontaneous AF, pacing-induced after-depolarizations, and AF were substantially reduced. Expression of mCAT markedly reduced persistent Na+ current–induced ryanodine receptor oxidation and dysfunction. In summary, increased persistent Na+ current in atrial cardiomyocytes, which is observed in patients with AF, induced atrial enlargement, fibrosis, mitochondrial dysmorphology, early after-depolarizations, and AF, all of which can be attenuated by resolving mitochondrial oxidative stress.

Authors

Uma Mahesh R. Avula, Haikel Dridi, Bi-xing Chen, Qi Yuan, Alexander N. Katchman, Steven R. Reiken, Amar D. Desai, Samantha Parsons, Haajra Baksh, Elaine Ma, Parmanand Dasrat, Ruiping Ji, Yejun Lin, Christine Sison, W. Jonathan Lederer, Humberto C. Joca, Christopher W. Ward, Maura Greiser, Andrew R. Marks, Steven O. Marx, Elaine Y. Wan

×

Figure 2

Expression of mitochondrial catalase does not attenuate F1759A-NaV1.5–induced prolongation of the action potential duration.

Options: View larger image (or click on image) Download as PowerPoint
Expression of mitochondrial catalase does not attenuate F1759A-NaV1.5–in...
(A) Representative limb-lead surface electrocardiograms of isoflurane-anesthetized nontransgenic control mice, F1759A, and F1759A-mCAT mice in normal sinus rhythm. Scale bar: 100 ms. (B) Graph of QT intervals. Mean ± SEM. One-way ANOVA, P < 0.0001; ** P < 0.01; *** P < 0.001 by Tukey’s multiple-comparison test. (C) Representative optical APD50 maps of right and left atria of nontransgenic, F1759A, and F1759-mCAT mice. APD maps (pacing at 10 Hz) for F1759A-NaV1.5 mice were obtained after hyperkalemia-induced conversion to sinus rhythm. Scale bar: 1 mm. (D and E) Graph showing maximal APD50 in left and right atria of NTG, F1759A-NaV1.5, and F1759A-mCAT mice. Mean ± SEM. One-way ANOVA, P < 0.001 for left atrium, P < 0.0001 for right atrium. *** P < 0.001; **** P < 0.0001 by Tukey’s multiple-comparison test. (F and G) Graphs of mean APD50. Mean ± SEM. P < 0.0001 by 1-way ANOVA; ** P< 0.01; **** P < 0.0001 by Tukey’s multiple-comparison test. (H and I) Graphs of APD50 dispersion. Mean ± SEM, 1-way ANOVA, P < 0.0001 for left atrium, P < 0.01 for right atrium. ** P <0.01; **** P < 0.0001 by Tukey’s multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts